Perle Bioscience perlebioscience.com


Public lists: Pharma Startups (6570)

Perle Bioscience is engaged in development of new pharmaceutical compositions and methods for reversing Type 1 and 2 Diabetes. Perle is setting the stage for usage of a new proprietary peptide therapy for generation of new insulin producing cells, which is a breakthrough with the potential to benefit millions of people.

Perle Bioscience is engaged in development of new pharmaceutical compositions and methods for reversing Type 1 and 2 Diabetes. Perle is setting the stage for usage of a new proprietary peptide therapy for generation of new insulin producing cells, wh...Show all

Company (Alive / Active)

All investors data 2 Investors

Phone: 843-568-2603

Fax:

520 Folly Road
Suite P212
 Charleston, 29412
 South Carolina, United States

Latest News

See more competitors data Competitors
Total Funding Date of Last Funding
Perle Bioscience $6.7M Dec 7, 2015

Web Traffic

Rank

Show (-10)

Engagement (PVPU)

Show (+1%)

Domain Authority Score
Show
Page Views Per Million (PVPM)
Show
Reach Per Million
Show

SEO Statistics

Domain Authority Score Show
Page Authority Score Show
No. External Links Show
No. Links Show

Web Traffic Statistics - Growth

Per Week Per Month Per 6 Months Per Year
Rank Login to see details
Page Views Per Million Login to see details
Page Views Per User Login to see details
Reach Per Million Login to see details

Related Perle Bioscience Jobs

jobs by Indeed job search

Investors

Investor Investor Type Location Participating Rounds
See all 2 investors
There is no Board of Directors data available for this company. Please select another tab.
There is no Competitors data available for this company. Please select another tab.

Patents

Title Application Date Patent Date Status
(Patent / Application)
Generation of new pancreatic beta cells Oct 26, 2012 Dec 06, 2016 Patent
Insulin independence among patients with diabetes utilizing an optimized hamster reg3 gamma peptide Aug 06, 2014 Apr 26, 2016 Patent
Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent Feb 15, 2013 Aug 19, 2014 Patent